The purpose of this article is to provide an overview of white light colon capsule endoscopy's current clinical application, concentrating on its most recent developments. Second-generation colon capsule endoscopy (CCE2) is approved by the FDA for use as an adjunctive test in patients with incomplete colonoscopy and within Europe in patients at average risk, those with incomplete colonoscopies or those unwilling to undergo conventional colonoscopies. Since the publication of European Society of GI Endoscopy guidelines on the use of CCE, there has been a significant increase in comparative studies on the diagnostic yield of CCE. This paper discusses CCE2 in further detail. It explains newly developed colon capsule system and the current status on the use of CCE, it also provides a comprehensive summary of systematic reviews on the implementation of CCE in colorectal cancer screening from a methodological perspective. Patients with ulcerative colitis can benefit from CCE2 in terms of assessing mucosal inflammation. As part of this review, performance of CCE2 for assessing disease severity in ulcerative colitis is compared with colonoscopy. Finally, an assessment if CCE can become a cost-effective clinical service overall.

中文翻译：

---

结肠胶囊内窥镜的临床效用：移动目标？

本文的目的是概述白光结肠胶囊内窥镜目前的临床应用，重点介绍其最新发展。第二代结肠胶囊内窥镜检查 (CCE2) 已获得 FDA 批准，可用作未完成结肠镜检查的患者以及欧洲普通风险患者、未完成结肠镜检查或不愿接受传统结肠镜检查的患者的辅助检查。自从欧洲胃肠道内窥镜学会关于 CCE 使用指南发布以来，关于 CCE 诊断率的比较研究显着增加。本文更详细地讨论了 CCE2。阐述了新开发的结肠胶囊系统和CCE的使用现状，并从方法学角度对CCE在结直肠癌筛查中的实施进行了系统综述。溃疡性结肠炎患者可以从 CCE2 评估粘膜炎症方面受益。作为本次综述的一部分，我们将 CCE2 评估溃疡性结肠炎疾病严重程度的性能与结肠镜检查进行了比较。最后，评估 CCE 是否可以成为一项总体上具有成本效益的临床服务。